ScreenerHero

GERN Geron Corporation

NAS · US · Healthcare · Biotechnology · geron.com
1.220USD+1.67%Mkt Cap: 783.82M $P/E: —

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap783.82M USD
Enterprise Value598.69M USD
Revenue (TTM)204.56M USD
Gross Profit179.14M USD
Net Income (TTM)-83.50M USD
Revenue/Share0.31 USD
Last Price1.220 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees258
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)30.25
PEG—
EV/EBITDA-17.20
EV/Revenue2.93
P/S3.80
P/B3.56
EPS (TTM)-0.11
EPS (Forward)0.04
52W Range
1.04019% of range2.010
52W High2.010 USD
52W Low1.040 USD
Profitability
Gross Margin97.42%
Oper. Margin-22.01%
EBITDA Margin-17.01%
Profit Margin-45.41%
ROE-36.97%
ROA-14.64%
Growth
Revenue Growth17.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-111.04M USD
CapEx (TTM)49.00K USD
FCF Margin-38.31%
FCF Yield-10.00%
Net Debt-178.70M USD
Net Debt/EBITDA5.14
Balance Sheet
Debt/Equity0.54
Current Ratio6.92
Quick Ratio5.04
Book Value/Sh0.34 USD
Cash/Share0.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1058:1000
Split DateJul 22, 2014
Analyst Consensus
Rating—
Target (Mean)4.250 USD
Upside (mean)+248.4%
Target Range3.000 USD – 6.000 USD
3.000+248.4% to mean6.000
# Analysts4
Ownership
Shares Out.642.47M
Float556.31M
Insiders0.08%
Institutions77.05%
Short Interest
Short Ratio8.3d
Short % Float12.87%
Short % Out.12.86%
Shares Short82.62M
Short (prev mo.)80.60M
Technical
SMA 501.412 (-13.6%)
SMA 2001.444 (-15.5%)
Beta0.61
S&P 52W Chg16.45%
Avg Vol (30d)9.18M
Avg Vol (10d)9.96M
Technical Indicators
RSI (14)37.8
MACD-0.0615
MACD Signal-0.0600
MACD Hist.-0.0015
BB Upper1.396 USD
BB Middle1.271 USD
BB Lower1.146 USD
BB Width19.66%
ATR (14)0.0613 USD
Vol Ratio (20d)1.24x